MODERNA (MRNA)

$31.19 0.07 (0.22%)

20:00 EDT MRNA Stock Quote Delayed 30 Minutes

The 3 Most Undervalued Biotech Stocks to Buy in September 2023

By Joel Baglole, InvestorPlace Contributor Sep 12, 2023

While these undervalued biotech stocks have struggled of late, they could surprise investors and prove to be long-term winners.

3 Meme Stocks That Could Actually Rebound in Q4

7 Biotech Stocks to Sell in September Before They Crash & Burn

3 Beaten-Down Biotech Stocks Bound for a Bounce Back

Volume:

Previous Close $32.12

Market Cap 12.01B

PE Ratio -3.36

EPS -9.2737

Volume (Avg. Vol.) 5.68M

Day's Range $31.02 - $32.50

52-Week Range $29.25 - $170.47

Dividend & Yield N/A (N/A)

MRNA Stock Predictions, Articles, and MODERNA News

7 F-Rated Biotech Stocks You Shouldn’t Touch With a 10-Foot Pole

By Louis Navellier and the InvestorPlace Research Staff Aug 25, 2023

There are some solid biotech stocks on the market. But there are many more that deserve an “F” rating from the Portfolio Grader.

MRNA Stock Alert: Why Is Moderna Up 7% Today?

By Chris MacDonald, InvestorPlace Contributor Aug 17, 2023

Investors in Moderna (MRNA) stock have received a boost today from reports that a late summer Covid wave could be on the horizon.

3 Pharma Stocks to Sell in August Before They Crash and Burn

By Joel Baglole, InvestorPlace Contributor Aug 11, 2023

Stay far away from these pharma stocks that are suffering from declining sales and weak pipelines of future products.

3 Healthcare Stocks to Sell in August Before They Crash and Burn

By Joel Baglole, InvestorPlace Contributor Aug 9, 2023

Steer clear of these healthcare stocks, each of which is struggling with significant problems that are impacting their earnings.

3 ‘Strong Buy’ Biotech Stocks You Should Be Loading Up On Now

By Jeremy Flint, InvestorPlace Contributor Aug 2, 2023

Biotech stocks can be a lucrative investment opportunity, these three biotech stocks to buy now are among analyst favorites.

3 Cheap Healthcare Stocks That Smart Investors Will Snap Up Now

By Joel Baglole, InvestorPlace Contributor Aug 1, 2023

While technology stocks have powered this year's market rally, shares of healthcare companies have trailed behind. The S&P 500 Healthcare Index is essentially flat year-to-date (down 0.71%) while the benchmark S&P 500 has gained 20% on the year.

7 Healthcare Stocks to Ditch Before They Make Your Portfolio Sick

By Louis Navellier and the InvestorPlace Research Staff Jul 31, 2023

For investors who choose wisely, profits in healthcare stocks can be spectacular. But the losses can also be dramatic if you choose poorly.

The 3 Most Undervalued Biotech Stocks to Buy Now: July 2023

By Marie Brodbeck, InvestorPlace Contributor Jul 24, 2023

These three undervalued biotech stocks could have plenty of room to run if their efforts to push out promising pipeline drugs are successful.

Obey the Sell Signals: 3 Blue-Chip Stocks to Let Go

By Chris Markoch, InvestorPlace Contributor Jul 20, 2023

The recent rally is starting to extend to include large-cap and blue-chip stocks, but there are still some blue-chip stocks to avoid.

7 Biotech Stocks to Sell in July

By Thomas Niel, InvestorPlace Contributor Jul 13, 2023

Running the gamut from large to small, and from commercial stage to clinical stage, these are seven top biotech stocks to sell in July.

3 Value Stocks to Consider Selling Before They Do Your Portfolio In

By Faizan Farooque, InvestorPlace Contributor Jul 5, 2023

Looking to protect your portfolio? Learn the art of portfolio management by selling bad value stocks and identifying the right time to sell.

3 Pharma Stocks That Have Big Investors Running for the Exit

By Joel Baglole, InvestorPlace Contributor Jun 28, 2023

Hedge funds, institutional investors and company insiders have been dumping shares of these risky pharma stocks.

7 Value Stocks to Dump Before They Decline Even Further

By Thomas Niel, InvestorPlace Contributor Jun 18, 2023

As the market remains in a "sell value stocks" state of mind, consider now the time to exit all positions in these seven low-quality value plays.

How to Retire Rich: Biotech Stocks Edition

By Josh Enomoto, InvestorPlace Contributor Jun 18, 2023

Thanks to its enormous and practically permanent relevancies, the biotech sector offers a great avenue for retirement planning stocks.

7 Stocks to Sell in June Before They Crash and Burn

By Alex Sirois, InvestorPlace Contributor Jun 13, 2023

Stocks to sell in June include some obvious and not-so-obvious names as multiple factors conspire, changing the market

Get Out Now! 3 Value Stocks That Are Poised to Plunge.

By Ian Bezek, InvestorPlace Contributor Jun 12, 2023

Investors like to get a bargain when putting money to work. But don't get tricked by these three apparent value stocks that are actually risky bets.

3 Biotech Stocks to Sell in June Before They Crash and Burn

By Joel Baglole, InvestorPlace Contributor Jun 6, 2023

The biotechnology sector has seen better days. From the Hedy days of the pandemic when companies were racing to develop a vaccine against Covid-19, the industry is now enduring a hangover as both demand and sales decline.

7 Stocks That Even Company Insiders are Selling

By Thomas Niel, InvestorPlace Contributor May 24, 2023

Having said all of this, instead of making broad generations as to whether insider selling is bullish or bearish, let's take a look at seven stocks insiders are selling, and see whether it's a sign to buy or a sign to sell.

Hero or Zero? 3 High-Risk Biotech Stocks to Make You Rich … or Broke.

By John Blankenhorn, InvestorPlace Contributor May 22, 2023

These biotech companies are swinging for the fences. They may hit homers, they may strike out. But you'll definitely want to watch them.

Warning! 3 Stocks That Are Waving Big Red Flags

By Joel Baglole, InvestorPlace Contributor May 14, 2023

Investors should steer clear of these risky stocks with big red flags until such time as the companies behind them can fix their issues.

MODERNA (MRNA)

The 3 Most Undervalued Biotech Stocks to Buy in September 2023

3 Meme Stocks That Could Actually Rebound in Q4

7 Biotech Stocks to Sell in September Before They Crash & Burn

3 Beaten-Down Biotech Stocks Bound for a Bounce Back

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

MODERNA (MRNA)

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

MRNA Stock Predictions, Articles, and MODERNA News

Subscriber Sign in